Summary
This laboratory study describes the development of a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) to detect the oncofetal antigen ROR1 in circulating exosomes, potentially applicable as a cancer biomarker. The authors optimised analytical parameters to improve specificity and sensitivity of exosome detection. As a methodological contribution, the clinical utility and translational significance would require subsequent validation in patient cohorts.
UK applicability
This analytical methodology could be adopted by UK diagnostic or research laboratories investigating exosome-based cancer biomarkers, though clinical validation in UK patient populations would be necessary before clinical deployment.
Key measures
DELFIA assay specificity and sensitivity for ROR1-positive exosome detection; analytical optimisation parameters
Outcomes reported
Development and optimisation of a DELFIA-based immunoassay method to detect oncofetal antigen ROR1 in circulating exosomes. The study reports analytical performance characteristics of the assay as a potential cancer biomarker detection platform.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.